BPC-157 + TB-500 Stack Protocol:
The Complete Research Guide
BPC-157 and TB-500 are individually among the most-studied repair peptides in preclinical literature. Combined, they target complementary axes of tissue regeneration — local angiogenesis and VEGF signalling (BPC-157) alongside systemic actin-driven cell migration (TB-500). This guide covers the mechanistic rationale for co-administration and common protocol designs used in published research.
Mechanistic Overview
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide that exerts its primary repair effects through upregulation of vascular endothelial growth factor (VEGF) and promotion of local angiogenesis. Studies in rodent tendon injury models demonstrate accelerated neovascularisation at the injury site within 48–72 hours of subcutaneous administration, compared to saline controls.
TB-500 (Thymosin Beta-4) operates through a fundamentally different mechanism: it sequesters G-actin monomers, promoting actin polymerisation, lamellipodia formation, and long-range cell migration. This systemic action makes TB-500 particularly relevant for injuries where local peptide concentration is insufficient to drive repair — deep tissue injuries, avascular structures, and multi-site pathology.
The mechanistic complementarity is the scientific justification for co-administration: BPC-157 builds the vascular infrastructure; TB-500 drives the cellular migration into that new vascular bed. Multiple animal model studies have used both compounds in combination, including a 2016 model of achilles tendon injury where the combination group showed superior histological repair compared to either peptide alone.
Research Protocol Designs
Loading Phase (Weeks 1–2)
Published rodent studies commonly use a loading approach for TB-500, reflecting its longer half-life relative to BPC-157. A representative loading protocol:
- BPC-157: 250–500 mcg administered subcutaneously, twice daily, proximal to injury site when possible
- TB-500: 5 mg administered subcutaneously, twice weekly during loading phase
- Duration: 2 weeks loading, transitioning to maintenance
Maintenance Phase (Weeks 3–12)
- BPC-157: 250–500 mcg subcutaneously, once or twice daily (continue throughout)
- TB-500: 5 mg subcutaneously, once weekly maintenance dose
- Total cycle: 8–12 weeks, with 4-week washout before repeating
Timing and Administration Notes
BPC-157 has a short half-life (estimated 1–4 hours in rodent models) and is generally administered twice daily in research protocols to maintain tissue-level presence throughout the day. TB-500, by contrast, shows effects persisting for several days following a single injection, supporting the weekly maintenance dosing pattern seen in studies.
Co-injection at the same site is not required and may not be advantageous — the systemic nature of TB-500 means remote administration produces equivalent tissue-level concentrations. BPC-157 local injection (perilesional) is used in some injury models, though subcutaneous distal administration also demonstrates efficacy in gut models, suggesting systemic distribution occurs.
Reconstitution Reference
Both compounds arrive lyophilised. For a standard 2mL reconstitution of a 5mg vial:
- Add 2mL bacteriostatic water → concentration: 2500 mcg/mL
- 250 mcg dose = 0.1mL = 10 units on a U-100 syringe
- 500 mcg dose = 0.2mL = 20 units on a U-100 syringe
- 5mg TB-500 dose = 2mL (full vial reconstitution volume)
Use our Peptide Reconstitution Calculator for other volumes and concentrations.
Supporting Compounds
Researchers frequently combine BPC-157 + TB-500 with:
- KPV — NF-kB inhibitor for systemic anti-inflammatory support during repair
- GHK-Cu — Copper tripeptide for collagen III synthesis and wound remodelling
- AOD-9604 — GH fragment with cartilage repair and chondrocyte effects
See the full Accelerated Repair Stack protocol for a structured combination approach.